Could a bone drug halt skeletal damage in kids with rare disease?
NCT ID NCT05419050
First seen Jan 23, 2026 · Last updated May 10, 2026 · Updated 15 times
Summary
This study tested a drug called denosumab in 15 children aged 4 to 14 with fibrous dysplasia, a rare bone disease that causes weak spots and fractures. The goal was to see if the drug could stop bone lesions from growing during childhood. Participants received injections every 4 weeks for 48 weeks and were monitored with scans and lab tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROUS DYSPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.